VUITY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for VUITY (VUITY).
VUITY (pilocarpine hydrochloride ophthalmic solution) 1.25% is a muscarinic receptor agonist. It induces miosis by contracting the iris sphincter muscle, increasing the eye's depth of focus and improving near visual acuity. It acts via the ciliary muscle to reduce the diameter of the pupil, creating a pinhole effect that enhances depth of focus.
| Metabolism | Pilocarpine is primarily metabolized by serum esterases and undergoes hepatic metabolism to inactive metabolites. |
| Excretion | Primarily via hepatic metabolism; inactive metabolites excreted in urine (approximately 90%) and feces (approximately 10%). |
| Half-life | Terminal half-life: 134 hours (range 110-170 hours). Clinical context: allows once-weekly dosing; steady-state achieved after 2-3 months. |
| Protein binding | Approximately 99% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Vd: 1.9 L/kg. Clinical meaning: indicates extensive tissue distribution, including ocular tissues. |
| Bioavailability | Ocular bioavailability: not systematically evaluated (topical administration). Systemic bioavailability after ocular dosing is negligible. |
| Onset of Action | Ocular administration: onset of action within 1 hour; peak IOP reduction at 8-12 hours. |
| Duration of Action | Duration of action: up to 7 days. Clinical note: once-weekly dosing maintains IOP reduction throughout the week. |
| Molecular Weight | 182.65 |
One drop of VUITY (pilocarpine 1.25% ophthalmic solution) instilled into each eye three times daily at approximately 6-8 hour intervals.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment as systemic absorption is minimal. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. |
| Geriatric use | No specific dosage adjustment recommended; use with caution due to potential increased risk of adverse effects such as blurred vision or headache. |
| 1st trimester | Data insufficient for human pregnancy; no fetal harm observed in animal studies at clinically relevant exposures. Use only if benefit outweighs risk. |
| 2nd trimester | No adequate human studies; animal reproduction studies show no risk. Caution advised. |
| 3rd trimester | Potential risk of systemic effects due to placental transfer; use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for VUITY (VUITY).
| Placental transfer | Carbachol is a small molecule (molecular weight <500 Da) and likely crosses the placenta; animal studies show distribution to fetal tissues. |
| Breastfeeding | Not known if carbachol (VUITY) is excreted in human milk. Due to potential for serious adverse reactions in nursing infants, consider importance of drug to mother and discontinue nursing or drug. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to carbachol or any componentAcute iritisAngle-closure glaucoma (predisposition)Asthma (risk of bronchospasm)BradycardiaHyperthyroidismPeptic ulcerParkinsonism
| Precautions | Risk of retinal detachment, especially in patients with pre-existing retinal disease or high myopia, Avoid use in patients with acute iritis or conditions where pupillary constriction is undesirable, May cause visual disturbances (e.g., decreased night vision, difficulty in dark adaptation) due to miosis, Potential for increased intraocular pressure in patients with narrow-angle glaucoma or angle-closure glaucoma, Systemic absorption may cause bradycardia, hypotension, bronchospasm, and increased GI motility |
| Food/Dietary | No specific food interactions for ophthalmic use. Oral pilocarpine may be affected by food, but ophthalmic absorption is negligible. Avoid alcohol if excessive tearing or blurred vision occurs, as it may impair judgment. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | No adequate studies in pregnant women; animal reproduction studies not conducted; based on drug class (carbonic anhydrase inhibitor), potential for fetal harm cannot be excluded; use only if clearly needed. |
| Fetal Monitoring | No specific monitoring required; consider periodic ophthalmic exams for maternal adverse effects; fetal monitoring not indicated. |
| Fertility Effects | No data on human fertility; animal studies not available; unlikely to affect fertility due to topical ocular administration. |
| Clinical Pearls | VUITY (pilocarpine hydrochloride ophthalmic solution) 1.25% is a muscarinic receptor agonist used for presbyopia. It induces miosis, creating a pinhole effect to improve near vision while minimally affecting distance vision. Onset of miosis is within 15 minutes, with duration up to 6 hours. Avoid use in patients with narrow-angle glaucoma or those at risk for retinal detachment. Advise patients of potential transient blurred vision and difficulty with night vision. |
| Patient Advice | Instill one drop in each eye once daily, or as directed by your eye doctor. · Use at the same time each day for consistent effect. · Do not touch the dropper tip to any surface to avoid contamination. · Remove contact lenses before instillation; wait at least 10 minutes before reinserting. · May cause temporary blurred vision, especially in low light; avoid driving or operating machinery until vision clears. · Report any eye pain, changes in vision, or signs of retinal detachment (flashes, floaters) immediately. · Keep bottle tightly closed when not in use; store at room temperature. |